Novel Perspectives in Pseudomyxoma Peritonei Treatment.
Antonio SommarivaMarco TonelloGiulia RigottoNayana LazzariPierluigi PilatiMaria Luisa CalabròPublished in: Cancers (2021)
Pseudomyxoma Peritonei (PMP) is an anatomo-clinical condition characterized by the implantation of neoplastic cells on peritoneal surfaces with the production of a large amount of mucin. The rarity of the disease precludes the evaluation of treatment strategies within randomized controlled trials. Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has proven to be the only therapeutic option with potential chances of cure and long-term disease control. The present review discusses the epidemiology, pathogenesis, clinical presentation and treatment of PMP, focusing on the molecular factors involved in tumor progression and mucin production that could be used, in the upcoming future, to improve patient selection for surgery and to expand the therapeutic armamentarium.
Keyphrases
- minimally invasive
- randomized controlled trial
- induced apoptosis
- coronary artery bypass
- squamous cell carcinoma
- systematic review
- risk factors
- escherichia coli
- cell death
- cell cycle arrest
- clinical trial
- poor prognosis
- radiation therapy
- cystic fibrosis
- risk assessment
- atrial fibrillation
- biofilm formation
- cell proliferation
- endoplasmic reticulum stress
- replacement therapy
- metastatic renal cell carcinoma